Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Squamous Cell Carcinoma of the Head and Neck (SCCHN)

In brief

The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Key facts

Study ID
NCT02499120
Run by
Pfizer
People needed
125
Starts
2015-09-10
Expected to finish
2022-09-07
Last updated by the study team
2023-09-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.